Connor Clark & Lunn Investment Management Ltd. Takes Position in Mirum Pharmaceuticals, Inc. $MIRM

Posted by Stanley Muller on Aug 25th, 2026

Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 420,063 shares of the company’s stock, valued at approximately $49,177,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.65% of Mirum Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter worth $513,945,000. William Blair Investment Management LLC bought a new position in shares of Mirum Pharmaceuticals during the second quarter valued at about $164,453,000. Janus Henderson Group PLC boosted its holdings in Mirum Pharmaceuticals by 21.4% during the fourth quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after purchasing an additional 1,067,722 shares during the last quarter. State Street Corp boosted its holdings in Mirum Pharmaceuticals by 59.2% during the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after purchasing an additional 797,088 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in Mirum Pharmaceuticals by 566.8% in the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after purchasing an additional 672,118 shares in the last quarter.

Mirum Pharmaceuticals Stock Up 0.4%

MIRM opened at $96.72 on Tuesday. Mirum Pharmaceuticals, Inc. has a twelve month low of $63.23 and a twelve month high of $130.00. The company’s 50-day moving average price is $111.11 and its two-hundred day moving average price is $101.87. The stock has a market cap of $6.28 billion, a price-to-earnings ratio of -6.65 and a beta of 0.52. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The company had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The company’s revenue for the quarter was up 37.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.12) EPS. As a group, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Robert W. Baird set a $123.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. Weiss Ratings raised Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a report on Thursday, August 6th. Morgan Stanley set a $137.00 price target on Mirum Pharmaceuticals in a research report on Thursday, August 6th. CLSA set a $146.00 price objective on Mirum Pharmaceuticals in a research report on Monday, June 15th. Finally, TD Cowen reduced their price objective on Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $137.33.

Get Our Latest Research Report on Mirum Pharmaceuticals

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 40,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the transaction, the senior vice president owned 1,274 shares of the company’s stock, valued at $127,400. This represents a 96.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Eric Bjerkholt sold 6,001 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the transaction, the chief financial officer owned 36,355 shares of the company’s stock, valued at $3,631,864.50. The trade was a 14.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 133,156 shares of company stock valued at $13,763,562. Company insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals Profile

(Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.